The biologics market is made up of companies that manufacture biological commodities derived from human DNA and genetically engineered proteins. Biologic goods include recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenic substances. Due to the growing prevalence of chronic diseases and rising demand for biologics globally, the market for biologics is expected to grow. Cancers include breast cancer, lung cancer, bladder cancer, prostate cancer, colorectal cancer, and skin cancer are all treated using biologics. Therefore, it is anticipated that an increase in the prevalence of different cancers will spur demand for biologics products and, as a result, market expansion. Additionally, expanding clinical investigations as well as rising demand and acceptance for novel therapies are projected to fuel market growth.
The projection period (2023-2030) will see a CAGR of 9.3% in the global Biologics Market.
Top Companies in the Biologics Industry:
Novartis AG
Novartis AG was founded in 1996 as a result of the combination of Sandoz and Ciba-Geigy. The headquarters of Novartis were located in Basel, Switzerland. It makes life better and longer. Around 140 nations have partners with Novartis AG. Novartis stated in September 2022 that it would invest in next-generation biotherapeutics by establishing a fully integrated, dedicated USD 300 million scientific environment to strengthen its capacity and capabilities for early technical development of biologics.
AstraZeneca PLC
AstraZeneca PLC is a multinational pharmaceutical and biotechnology firm that is British and Swedish. With its headquarters in England, the UK, it was established in 1999. It works in more than 100 nations.. In December 2021, AstraZeneca started working on the subsequent generation of drug delivery systems. Using a balanced strategy of internally produced technology and external collaborations, the company is striving to develop medications and delivery agents that can reach difficult-to-reach intracellular targets. It focuses on lipid nanoparticles (LNPs) as a potential and distinctive delivery system for nucleotide-based treatments that induce the creation of proteins in cells. The most cutting-edge method for mRNA delivery, LNPs have a track record for delivering nucleic acids. LNPs can transport mRNA into cells after intravenous, subcutaneous, or pulmonary infusion and trigger the production of cellular proteins. The company is currently focusing on enhancing the efficacy and safety profile of the medicine delivery system.
Bayer AG
Bayer AG is a German multinational pharmaceutical and biotechnology firm that was formed in 1863 and is one of the world's largest pharmaceutical corporations. The company's headquarters are in Leverkusen, Germany. Bayer has 83 offices worldwide, including Canada, Mexico, Germany, and Switzerland. In order to develop biological solutions in areas including nitrogen optimization, carbon sequestration, and next-generation crop protection/Open Innovation, Ginkgo Bioworks will join Bayer as a multi-year strategic partner in October 2022. By utilizing the global open innovation ecosystem, sourcing aims to accelerate the R&D process for biological products. Bayer will keep working to improve Joyn Bio's nitrogen fixation technology in order to eventually replace synthetic fertilizers.